CD274 and non-small cell lung carcinoma: The phase 3 IMPOWER010 trial showed a benefit in disease-free survival (DFS) by adding anti-PD-L1 atezolizumab for 1 year after adjuvant platinum-based chemotherapy in stage II-IIIA NSCLC patients, with a greater benefit in patients with PD-L1 expression ≥1%, with a gain in DFS (hazard ratio (HR)=0.66; 95% confidence interval (95%CI)=0.67-0.99, p=0.04) and a trend towards longer OS.(8)